R. Amado, M. Wolf, M. Peeters, E. Van-cutsem, S. Siena et al., Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1660, 2008.
DOI : 10.1200/JCO.2007.14.7116

A. Lievre, J. Bachet, V. Boige, A. Cayre, L. Corre et al., Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-383, 2008.
DOI : 10.1200/JCO.2007.12.5906

URL : https://hal.archives-ouvertes.fr/hal-00363737

O. Kranenburg, The KRAS oncogene: Past, present, and future, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1756, issue.2, pp.81-83, 2005.
DOI : 10.1016/j.bbcan.2005.10.001

M. Srinivasan, D. Sedmak, and S. Jewell, Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids, The American Journal of Pathology, vol.161, issue.6, pp.1961-71, 2002.
DOI : 10.1016/S0002-9440(10)64472-0

M. Gilbert, T. Haselkorn, M. Bunce, J. Sanchez, S. Lucas et al., The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues???Which Methods Are Useful When?, PLoS ONE, vol.35, issue.6, p.537, 2007.
DOI : 10.1371/journal.pone.0000537.s002

M. Ronaghi, B. Pettersson, M. Uhlen, and P. Nyren, PCR-introduced loop structure as primer in DNA sequencing, Biotechniques, vol.25, pp.876-884, 1998.

J. Bos, ras oncogenes in human cancer: a review, Cancer Res, vol.49, pp.4682-4691, 1989.

C. Oliveira, J. Westra, D. Arango, M. Ollikainen, E. Domingo et al., Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status, Human Molecular Genetics, vol.13, issue.19, pp.2303-2314, 2004.
DOI : 10.1093/hmg/ddh238

A. Ahmadian, M. Ehn, and S. Hober, Pyrosequencing: History, biochemistry and future, Clinica Chimica Acta, vol.363, issue.1-2, pp.83-94, 2006.
DOI : 10.1016/j.cccn.2005.04.038

W. Akerley, Erlotinib as first-time treatment for untreated advance stage NSCLC with good prognosis, J Clin Oncol, vol.24, p.408, 2006.

A. Alberg, M. Brock, and J. Samet, Epidemiology of Lung Cancer: Looking to the Future, Journal of Clinical Oncology, vol.23, issue.14, pp.3175-3185, 2005.
DOI : 10.1200/JCO.2005.10.462

R. Amado, M. Wolf, M. Peeters, E. Van-cutsem, S. Siena et al., Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1634, 2008.
DOI : 10.1200/JCO.2007.14.7116

C. Arteaga, The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia, J Clin Oncol, vol.19, pp.32-40, 2001.

H. Asano, S. Toyooka, M. Tokumo, K. Ichimura, K. Aoe et al., Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay, Clinical Cancer Research, vol.12, issue.1, pp.43-48, 2006.
DOI : 10.1158/1078-0432.CCR-05-0934

M. Beasley, E. Brambilla, and W. Travis, The 2004 World Health Organization classification of lung tumors, Seminars in Roentgenology, vol.40, issue.2, 2005.
DOI : 10.1053/j.ro.2005.01.001

D. Bell, T. Lynch, S. Haserlat, P. Harris, R. Okimoto et al., Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non???Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials, Journal of Clinical Oncology, vol.23, issue.31, pp.8081-8092, 2005.
DOI : 10.1200/JCO.2005.02.7078

A. Benhamiche-bouvier, F. Clinard, J. Phelip, E. Rassiat, and J. Faivre, Colorectal cancer prevalence in France, European Journal of Cancer Prevention, vol.9, issue.5, pp.303-307, 2000.
DOI : 10.1097/00008469-200010000-00003

F. Blanchon, M. Grivaux, T. Collon, M. Zureik, H. Barbieux et al., Epidemiologic of primary bronchial carcinoma management in the general French hospital centers], Rev Mal Respir, vol.19, pp.727-734, 2002.

P. Boffetta, Epidemiology of environmental and occupational cancer, Oncogene, vol.23, issue.38, pp.6392-6403, 2004.
DOI : 10.1038/sj.onc.1207715

J. Bonner, K. Raisch, H. Trummell, F. Robert, R. Meredith et al., Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers, J Clin Oncol, vol.18, pp.47-53, 2000.

J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin et al., Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.354, issue.6, pp.567-578, 2006.
DOI : 10.1056/NEJMoa053422

J. Bos, ras oncogenes in human cancer: a review, Cancer Res, vol.49, pp.4682-4689, 1989.

M. Boutron-ruault, P. Senesse, S. Meance, C. Belghiti, and J. Faivre, Energy Intake, Body Mass Index, Physical Activity, and the Colorectal Adenoma-Carcinoma Sequence, Nutrition and Cancer, vol.39, issue.1, pp.50-57, 2001.
DOI : 10.1207/S15327914nc391_7

M. Boutron, J. Faivre, M. Dop, V. Quipourt, and P. Senesse, Tobacco, alcohol, and colorectal tumors: a multistep process, Am J Epidemiol, vol.141, pp.1038-1046, 1995.

E. Brambilla, W. Travis, T. Colby, C. B. Shimosato, and Y. , The new World Health Organization classification of lung tumours, European Respiratory Journal, vol.18, issue.6, pp.1059-1068, 2001.
DOI : 10.1183/09031936.01.00275301

M. Brink, A. De-goeij, M. Weijenberg, G. Roemen, M. Lentjes et al., K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study, Carcinogenesis, vol.24, issue.4, pp.703-710, 2003.
DOI : 10.1093/carcin/bgg009

C. Butts, D. Bodkin, E. Middleman, C. Englund, D. Ellison et al., Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.36, pp.5777-5784, 2007.
DOI : 10.1200/JCO.2007.13.0856

P. Carter, Improving the efficacy of antibody-based cancer therapies, Nature Reviews Cancer, vol.1, issue.2, pp.118-129, 2001.
DOI : 10.1038/35101072

T. Chin, D. Anuar, R. Soo, M. Salto-tellez, W. Li et al., Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC, Clinical Chemistry, vol.53, issue.1, pp.62-70, 2007.
DOI : 10.1373/clinchem.2006.074831

F. Ciardiello, R. Bianco, V. Damiano, D. Lorenzo, S. Pepe et al., Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225, Clin Cancer Res, vol.5, pp.909-916, 1999.

F. Ciardiello and G. Tortora, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res, vol.7, pp.2958-2970, 2001.

A. Citri and K. Skaria, The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003.
DOI : 10.1016/S0014-4827(02)00101-5

S. Clayton, F. Scott, J. Walker, K. Callaghan, K. Haque et al., K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification, Clin Chem, vol.46, pp.1929-1938, 2000.

. Clinicaltrials and . Gov, website de l'US National Institute of Health relative aux essais cliniques, dernière consultation le 20.10, 2009.

V. Cohen, J. Agulnik, J. Jarry, G. Batist, D. Small et al., Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer, Cancer, vol.12, issue.12, pp.2858-2865, 2006.
DOI : 10.1002/cncr.22331

J. Crawford, A. Sandler, L. Hammond, J. Schiller, C. Belani et al., ABX-EGF in combination with paclitaxel and carboplatine for advanced non-small cell lung cancer (NSCLC), J Clin Oncol, vol.22, p.14, 2004.

D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg et al., Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004.
DOI : 10.1056/NEJMoa033025

B. Dautzenburg and G. Choukroun, Cancers bronchopulmonaires primitives non à petites cellules et tumeurs à malignité réduite. EMC-pneumologie 6-002-H-20, p.16, 1998.

W. De-roock, H. Piessevaux, D. Schutter, J. Janssens, M. et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.19, issue.3, pp.508-515, 2008.
DOI : 10.1093/annonc/mdm496

A. Gazdar, H. Shigematsu, J. Herz, and J. Minna, Mutations and addiction to EGFR: the Achilles ???heal??? of lung cancers?, Trends in Molecular Medicine, vol.10, issue.10, pp.481-486, 2004.
DOI : 10.1016/j.molmed.2004.08.008

G. Giaccone, R. Herbst, C. Manegold, G. Scagliotti, R. Rosell et al., Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non???Small-Cell Lung Cancer: A Phase III Trial???INTACT 1, Journal of Clinical Oncology, vol.22, issue.5, pp.777-784, 2004.
DOI : 10.1200/JCO.2004.08.001

G. Giaccone, R. Gallegos, L. Chevalier, T. Thatcher, N. Smit et al., Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study, Clinical Cancer Research, vol.12, issue.20, pp.6049-6055, 2006.
DOI : 10.1158/1078-0432.CCR-06-0260

M. Gilbert, T. Haselkorn, M. Bunce, J. Sanchez, S. Lucas et al., The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues???Which Methods Are Useful When?, PLoS ONE, vol.35, issue.6, p.537, 2007.
DOI : 10.1371/journal.pone.0000537.s002

N. Goldstein and M. Armin, Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma, Cancer, vol.43, issue.5, pp.1331-1346, 2001.
DOI : 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M

A. Goncalves, S. Esteyries, B. Taylor-smedra, A. Lagarde, M. Ayadi et al., A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment, BMC Cancer, vol.91, issue.21, p.169, 2008.
DOI : 10.1073/pnas.91.21.10217

A. Gschwind, O. Fischer, and A. Ullrich, Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy, Nature Reviews Cancer, vol.4, issue.5, pp.361-370, 2004.
DOI : 10.1038/nrc1360

S. Han, T. Kim, Y. Jeon, P. Hwang, S. Im et al., Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation, Clinical Cancer Research, vol.12, issue.8, pp.2538-2544, 2006.
DOI : 10.1158/1078-0432.CCR-05-2845

N. Hanna, R. Lilenbaum, R. Ansari, T. Lynch, R. Govindan et al., Phase II Trial of Cetuximab in Patients With Previously Treated Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.24, issue.33, pp.5253-5258, 2006.
DOI : 10.1200/JCO.2006.08.2263

R. Herbst, G. Giaccone, J. Schiller, R. Natale, V. Miller et al., Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non???Small-Cell Lung Cancer: A Phase III Trial???INTACT 2, Journal of Clinical Oncology, vol.22, issue.5, 2004.
DOI : 10.1200/JCO.2004.07.215

W. Hilbe, M. Dlaska, H. Duba, S. Dirnhofer, W. Eisterer et al., Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: Comparison with immunohistochemistry and clinico-pathological features, International Journal of Oncology, vol.23, pp.1121-1126, 2003.
DOI : 10.3892/ijo.23.4.1121

C. Hill and F. Doyon, The frequency of cancer in France in year 2002, and trends since 1968], Bull Cancer, vol.93, pp.7-11, 2006.

F. Hirsch, M. Varella-garcia, P. Bunn, J. , D. Maria et al., Epidermal Growth Factor Receptor in Non???Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis, Journal of Clinical Oncology, vol.21, issue.20, pp.3798-3807, 2003.
DOI : 10.1200/JCO.2003.11.069

T. Holbro, G. Civenni, and N. Hynes, The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003.
DOI : 10.1016/S0014-4827(02)00099-X

T. Holbro and N. Hynes, : Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.195-217, 2004.
DOI : 10.1146/annurev.pharmtox.44.101802.121440

R. Hung, J. Mckay, V. Gaborieau, P. Boffetta, M. Hashibe et al., A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25, Nature, vol.38, issue.7187, pp.633-637, 2008.
DOI : 10.1038/nature06885

URL : https://hal.archives-ouvertes.fr/cea-00944415

N. Hynes and H. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-354, 2005.
DOI : 10.1021/jm00130a020

D. Irmer, J. Funk, and A. Blaukat, EGFR kinase domain mutations ??? functional impact and relevance for lung cancer therapy, Oncogene, vol.37, issue.39, pp.5693-5701, 2007.
DOI : 10.1038/sj.onc.1210383

T. Itabashi, C. Maesawa, M. Uchiyama, T. Higuchi, and T. Masuda, Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes, International Journal of Oncology, vol.24, pp.687-696, 2004.
DOI : 10.3892/ijo.24.3.687

P. Janne, A. Borras, Y. Kuang, A. Rogers, V. Joshi et al., A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening, Clinical Cancer Research, vol.12, issue.3, pp.751-758, 2006.
DOI : 10.1158/1078-0432.CCR-05-2047

A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu et al., Cancer Statistics, 2008, Cancer statistics, pp.71-96, 2008.
DOI : 10.3322/CA.2007.0010

W. Karnes, . Jr, S. Weller, P. Adjei, T. Kottke et al., Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells?????????, Gastroenterology, vol.114, issue.5, pp.930-939, 1998.
DOI : 10.1016/S0016-5085(98)70312-9

H. Kimura, K. Kasahara, M. Kawaishi, H. Kunitoh, T. Tamura et al., Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non-Small-Cell Lung Cancer, Clinical Cancer Research, vol.12, issue.13, pp.3915-3921, 2006.
DOI : 10.1158/1078-0432.CCR-05-2324

B. Kochupurakkal, D. Harari, D. Segni, A. Maik-rachline, G. Lyass et al., Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity, Journal of Biological Chemistry, vol.280, issue.9, pp.8503-8512, 2005.
DOI : 10.1074/jbc.M413919200

T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida et al., Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib, Clinical Cancer Research, vol.12, issue.19, pp.5764-5769, 2006.
DOI : 10.1158/1078-0432.CCR-06-0714

O. Kranenburg, The KRAS oncogene: Past, present, and future, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1756, issue.2, pp.81-82, 2005.
DOI : 10.1016/j.bbcan.2005.10.001

D. Krause and R. Van-etten, Tyrosine Kinases as Targets for Cancer Therapy, New England Journal of Medicine, vol.353, issue.2, pp.172-187, 2005.
DOI : 10.1056/NEJMra044389

M. Kris, R. Natale, R. Herbst, T. Lynch, J. Prager et al., Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-2158, 2003.
DOI : 10.1001/jama.290.16.2149

M. Krypuy, G. Newnham, D. Thomas, M. Conron, and A. Dobrovic, High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer, BMC Cancer, vol.52, issue.12, p.295, 2006.
DOI : 10.1373/clinchem.2006.068205

O. Lababede, M. Meziane, and T. Rice, TNM Staging of Lung Cancer, Chest, vol.115, issue.1, pp.233-235, 1999.
DOI : 10.1378/chest.115.1.233

J. Lamoril, N. Ameziane, J. Deybach, P. Bouizegarène, and M. Bogard, DNA sequencing technologies: A revolution in motion, pp.260-279, 2008.

L. Faou, A. Scemama, and O. , Epidemiology of tobacco smoking], Rev Mal Respir, vol.22, pp.8-27, 2005.

J. Lee, Y. Soung, S. Kim, W. Park, S. Nam et al., Absence ofEGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer, International Journal of Cancer, vol.86, issue.3, pp.510-511, 2005.
DOI : 10.1002/ijc.20591

A. Lievre, J. Bachet, L. Corre, D. Boige, V. Landi et al., KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3995, 2006.
DOI : 10.1158/0008-5472.CAN-06-0191

A. Lievre, J. Bachet, V. Boige, A. Cayre, L. Corre et al., Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-379, 2008.
DOI : 10.1200/JCO.2007.12.5906

URL : https://hal.archives-ouvertes.fr/hal-00363737

R. Lilenbaum, The Evolving Role of Cetuximab in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.12, issue.14, pp.4432-4435, 2006.
DOI : 10.1158/1078-0432.CCR-06-0097

R. Lilenbaum, R. Axerold, S. Thomas, A. Dowlati, L. Seigel et al., Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, J Clin Oncol N Engl J Med, vol.24, issue.350, pp.2129-2139, 2004.

T. Lynch, T. Patel, and L. Dreisbach, A randomized multicenter phase III study of cetuximab (Erbitux ® ) in combination with Taxane/Carboplatin vs Taxane/Carboplatin alone first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC), th World Conference on Lung Cancer, pp.340-341, 2002.

M. Mackenzie, H. Hirte, G. Glenwood, M. Jean, R. Goel et al., A phase II trial of ZD1839 (Iressa?) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer, Investigational New Drugs, vol.17, issue.(11 suppl 12), pp.165-170, 2005.
DOI : 10.1007/s10637-005-5862-9

P. Miettinen, J. Berger, J. Meneses, Y. Phung, R. Pedersen et al., Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor, Nature, vol.376, issue.6538, pp.337-341, 1995.
DOI : 10.1038/376337a0

W. Miller, H. Earp, and N. Raab-traub, The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor, J Virol, vol.69, pp.4390-4398, 1995.

S. Modi and A. Seidman, An update on epidermal growth factor receptor inhibitors, Current Oncology Reports, vol.20, issue.Suppl 2, pp.47-55, 2002.
DOI : 10.1007/s11912-002-0047-6

R. Morinaga, I. Okamoto, Y. Fujita, T. Arao, M. Sekijima et al., amplification in advanced non-small cell lung cancer, Cancer Science, vol.24, issue.12, pp.2455-2460, 2008.
DOI : 10.1111/j.1349-7006.2008.00962.x

M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-bianchi et al., Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, The Lancet Oncology, vol.6, issue.5, pp.279-286, 2005.
DOI : 10.1016/S1470-2045(05)70102-9

D. Moscatello, M. Holgado-madruga, A. Godwin, G. Ramirez, G. Gunn et al., Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors, Cancer Res, vol.55, pp.5536-5539, 1995.

D. Moscatello, M. Holgado-madruga, D. Emlet, R. Montgomery, and A. Wong, Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor, Journal of Biological Chemistry, vol.273, issue.1, pp.200-206, 1998.
DOI : 10.1074/jbc.273.1.200

H. Nagahara, K. Mimori, M. Ohta, T. Utsunomiya, H. Inoue et al., Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma, Clinical Cancer Research, vol.11, issue.4, pp.1368-1371, 2005.
DOI : 10.1158/1078-0432.CCR-04-1894

R. Nicholson, J. Gee, and M. Harper, EGFR and cancer prognosis, European Journal of Cancer, vol.37, issue.4, pp.9-15, 2001.
DOI : 10.1016/S0959-8049(01)00231-3

S. Noonberg and C. Benz, Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily, Drugs, vol.11, issue.4, pp.753-767, 2000.
DOI : 10.2165/00003495-200059040-00003

S. Ogino, T. Kawasaki, M. Brahmandam, L. Yan, M. Cantor et al., Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing, The Journal of Molecular Diagnostics, vol.7, issue.3, pp.413-421, 2005.
DOI : 10.1016/S1525-1578(10)60571-5

C. Oliveira, J. Westra, D. Arango, M. Ollikainen, E. Domingo et al., Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status, Human Molecular Genetics, vol.13, issue.19, pp.2303-2311, 2004.
DOI : 10.1093/hmg/ddh238

J. Overholser, M. Prewett, A. Hooper, H. Waksal, and D. Hicklin, Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice, Cancer, vol.151, issue.1, pp.74-82, 2000.
DOI : 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K

J. Paez, P. Janne, J. Lee, S. Tracy, H. Greulich et al., EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, Science, vol.304, issue.5676, pp.1497-1500, 2004.
DOI : 10.1126/science.1099314

Q. Pan, W. Pao, and M. Ladanyi, Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas, The Journal of Molecular Diagnostics, vol.7, issue.3, pp.396-403, 2005.
DOI : 10.1016/S1525-1578(10)60569-7

W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proceedings of the National Academy of Sciences, vol.101, issue.36, pp.13306-13311, 2004.
DOI : 10.1073/pnas.0405220101

W. Pao and V. Miller, Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non???Small-Cell Lung Cancer: Current Knowledge and Future Directions, Journal of Clinical Oncology, vol.23, issue.11, pp.2556-2568, 2005.
DOI : 10.1200/JCO.2005.07.799

W. Pao, V. Miller, K. Politi, G. Riely, R. Somwar et al., Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain, PLoS Medicine, vol.9, issue.3, p.73, 2005.
DOI : 10.1371/journal.pmed.0020073.sd001

W. Pao, T. Wang, G. Riely, V. Miller, Q. Pan et al., KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib, PLoS Medicine, vol.104, issue.1, p.17, 2005.
DOI : 10.1371/journal.pmed.0020017.sd003

W. Pao and V. Miller, Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non???Small-Cell Lung Cancer: Current Knowledge and Future Directions, Journal of Clinical Oncology, vol.23, issue.11, pp.2556-2568, 2005.
DOI : 10.1200/JCO.2005.07.799

W. Pao and M. Ladanyi, Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method, Clinical Cancer Research, vol.13, issue.17, pp.4954-4955, 2007.
DOI : 10.1158/1078-0432.CCR-07-1387

R. Perez-soler, A. Chachoua, L. Hammond, E. Rowinsky, M. Huberman et al., Determinants of Tumor Response and Survival With Erlotinib in Patients With Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.16, pp.3238-3247, 2004.
DOI : 10.1200/JCO.2004.11.057

R. Peto, S. Darby, H. Deo, P. Silcocks, E. Whitley et al., Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies, BMJ, vol.321, issue.7257, pp.323-329, 2000.
DOI : 10.1136/bmj.321.7257.323

A. Poehlmann, D. Kuester, F. Meyer, H. Lippert, A. Roessner et al., K-ras mutation detection in colorectal cancer using the Pyrosequencing technique, Pathology - Research and Practice, vol.203, issue.7, pp.489-497, 2007.
DOI : 10.1016/j.prp.2007.06.001

J. Pollard, Opinion: Tumour-educated macrophages promote tumour progression and metastasis, Nature Reviews Cancer, vol.4, issue.1, pp.71-78, 2004.
DOI : 10.1038/nrc1256

N. Prenzel, O. Fischer, S. Streit, S. Hart, and A. Ullrich, The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification, Endocrine Related Cancer, vol.8, issue.1, pp.11-31, 2001.
DOI : 10.1677/erc.0.0080011

M. Prewett, A. Hooper, R. Bassi, L. Ellis, H. Waksal et al., Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts, Clin Cancer Res, vol.8, pp.994-1003, 2002.

L. Remontet, J. Esteve, A. Bouvier, P. Grosclaude, G. Launoy et al., Cancer incidence and mortality in France over the period, Rev Epidemiol Sante Publique, vol.51, pp.3-30, 1978.
URL : https://hal.archives-ouvertes.fr/hal-00428273

M. Ronaghi, B. Pettersson, M. Uhlen, and P. Nyren, PCR-introduced loop structure as primer in DNA sequencing, Biotechniques, vol.25, pp.876-878, 1998.

M. Ronaghi, M. Uhlen, and P. Nyren, DNA SEQUENCING:A Sequencing Method Based on Real-Time Pyrophosphate, Science, vol.281, issue.5375, pp.363-365, 1998.
DOI : 10.1126/science.281.5375.363

R. Rosell, R. G. Szczesna, A. Ramlau, R. Constenla, M. Mennecier et al., Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer, Annals of Oncology, vol.19, issue.2, pp.362-369, 2008.
DOI : 10.1093/annonc/mdm474

D. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995.
DOI : 10.1016/1040-8428(94)00144-I

L. Saltz, N. Meropol, P. Loehrer, . Sr, M. Needle et al., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1208, 2004.
DOI : 10.1200/JCO.2004.10.182

L. Saltz, H. Lenz, and H. Hochster, Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer, Journal of Clinical Oncology, vol.23, issue.16_suppl, pp.3508-1205, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.3508

M. Sant, R. Capocaccia, M. Coleman, F. Berrino, G. Gatta et al., Cancer survival increases in Europe, but international differences remain wide, European Journal of Cancer, vol.37, issue.13, pp.1659-1667, 2001.
DOI : 10.1016/S0959-8049(01)00206-4

J. Sato, T. Kawamoto, A. Le, J. Mendelsohn, J. Polikoff et al., Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors, Mol Biol Med, vol.1, pp.511-529, 1983.

J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler et al., Comparison of Four Chemotherapy Regimens for Advanced Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.346, issue.2, pp.92-98, 2002.
DOI : 10.1056/NEJMoa011954

A. Schreiber, I. Lax, Y. Yarden, Z. Eshhar, and J. Schlessinger, Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor., Proceedings of the National Academy of Sciences, vol.78, issue.12, pp.7535-7539, 1981.
DOI : 10.1073/pnas.78.12.7535

L. Sequist, D. Bell, T. Lynch, and D. Haber, Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.5, pp.587-595, 2007.
DOI : 10.1200/JCO.2006.07.3585

N. Shah, M. Kris, W. Pao, L. Tyson, B. Pizzo et al., Practical Management of Patients With Non???Small-Cell Lung Cancer Treated With Gefitinib, Journal of Clinical Oncology, vol.23, issue.1, pp.165-174, 2005.
DOI : 10.1200/JCO.2005.04.057

S. Sharma, D. Bell, J. Settleman, and D. Haber, Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-181, 2007.
DOI : 10.1038/nrc2088

F. Shepherd, P. Rodrigues, T. Ciuleanu, E. Tan, V. Hirsh et al., Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-132, 2005.
DOI : 10.1056/NEJMoa050753

T. Shields, Surgical therapy for carcinoma of the lung, Clin Chest Med, vol.14, pp.121-147, 1993.

H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki et al., Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers, JNCI Journal of the National Cancer Institute, vol.97, issue.5, pp.339-346, 2005.
DOI : 10.1093/jnci/dji055

M. Sibilia and E. Wagner, Strain-dependent epithelial defects in mice lacking the EGF receptor, Science, vol.269, issue.5221, pp.234-238, 1995.
DOI : 10.1126/science.7618085

M. Sonobe, T. Manabe, H. Wada, and F. Tanaka, Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma, British Journal of Cancer, vol.2, issue.3, pp.355-363, 2005.
DOI : 10.1038/sj.bjc.6602707

Y. Soung, J. Lee, S. Kim, S. Seo, W. Park et al., Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas, Virchows Archiv, vol.62, issue.5, pp.483-488, 2005.
DOI : 10.1007/s00428-005-1254-y

S. Spiro and J. Porter, Lung Cancer???Where Are We Today?, American Journal of Respiratory and Critical Care Medicine, vol.166, issue.9, pp.1166-1196, 2002.
DOI : 10.1164/rccm.200202-070SO

M. Srinivasan, D. Sedmak, and S. Jewell, Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids, The American Journal of Pathology, vol.161, issue.6, pp.1961-1971, 2002.
DOI : 10.1016/S0002-9440(10)64472-0

S. Straight, B. Herman, and D. Mccance, The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes, J Virol, vol.69, pp.3185-3192, 1995.

N. Sueoka, A. Sato, H. Eguchi, K. Komiya, T. Sakuragi et al., Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients, Journal of Cancer Research and Clinical Oncology, vol.29, issue.2, pp.93-102, 2007.
DOI : 10.1007/s00432-006-0144-2

K. Sugio, H. Uramoto, K. Ono, T. Oyama, T. Hanagiri et al., Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking, British Journal of Cancer, vol.11, issue.6, pp.896-903, 2006.
DOI : 10.1016/j.lungcan.2005.08.006

J. Tabernero, E. Van-cutsem, E. Diaz-rubio, A. Cervantes, Y. Humblet et al., Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.25, issue.33, pp.5225-5232, 2007.
DOI : 10.1200/JCO.2007.13.2183

T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno et al., Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.23, issue.28, pp.6829-6837, 2005.
DOI : 10.1200/JCO.2005.01.0793

Y. Tan, Y. Liu, K. Eu, P. Ang, W. Li et al., Detection of BRAF V600E mutation by pyrosequencing, Pathology, vol.40, issue.3, pp.295-298, 2008.
DOI : 10.1080/00313020801911512

N. Thatcher, A. Chang, P. Parikh, P. Rodrigues, T. Ciuleanu et al., Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), The Lancet, vol.366, issue.9496, pp.1527-1537, 2005.
DOI : 10.1016/S0140-6736(05)67625-8

R. Thomas, E. Nickerson, J. Simons, P. Janne, T. Tengs et al., Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing, Rothberg JM, Meyerson M Nat Med, vol.12, pp.852-855, 2006.

D. Threadgill, A. Dlugosz, L. Hansen, T. Tennenbaum, U. Lichti et al., Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype of erlotinib versus placebo in the treatment of non-small cell lung cancer, Science J Clin Oncol, vol.269, issue.24, pp.230-234, 1995.

M. Tsao, C. Zhu, and A. Sakurada, An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 stud ASSTRACT 8 aogro un<1 : Eplclonnlll Otowfl FK1at. lyrt>IOne IGnoH 1n1>1Mc:n (EGFR.fl(l1f, l>y. Alflo.q. , n no1 0, 2006.

_. Oicl-'ovl<, ~. , and .. , prl<liclf,oool.incxyolEOFR-TKl .. ll.y.,en01uMC1.,dnlUlpnH:llCO. n ... a. 1ori, pp.1-1

E. Metic-@bullet, J. .. Oan-fleconcora....., . Thto, and . F@bulletsh, P?"i:>l0gl011 p.,t1 ,. H torm.:1 . -"'t>otomt1tOC>J-.bUl"ol'lr'Olwulo..,...uoto"oOl>lllyoleocnc.,!?lopolformO!Omlll<« uuyonpwll!lwl, Ot001 .... lt<l!n>mn0t1·tnlOl<nl NSIWWlltn101n(F)Wlt\O

1. T. Co,....-_.-t-'nutlt..., ONA?"1r-.c?1ol, tcm 7 ? ..,n;JIUlly!HOC1it<INSCLCofwhJçn

C. .. Eol-'rf and _. , 0'1'1toNSAI 1'llln'IOcllnell>OlfK1a oeoi:Ror><1~, 1lnelll>Ot.,0<1"0M1'?cap.oty !Og .... COt1Wd..,l!~ l l